肺炎球菌性疾病免疫预防专家共识(2017版)

被引：58

作者：

王华庆

安志杰

机构：

[1] 中华预防医学会和中华预防医学会疫苗与免疫分会

来源：

中国预防医学杂志 | 2018年 / 19卷 / 03期

关键词：

肺炎链球菌; 肺炎球菌性疾病; 肺炎球菌多糖结合疫苗; 肺炎球菌多糖疫苗; 专家共识;

D O I：

10.16506/j.1009-6639.2018.03.001

中图分类号：

R515 [细菌传染病、球菌传染病];

学科分类号：

100401 ;

摘要：

肺炎球菌性疾病是全球严重的公共卫生问题之一,也是导致我国儿童及成人发病和死亡的重要原因。临床治疗以抗生素为主,由于抗生素的广泛应用,肺炎链球菌的耐药性问题日益严重。因此,采用肺炎球菌疫苗预防肺炎球菌性疾病并减少细菌的耐药性,尤为必要和迫切。本文在世界卫生组织关于肺炎球菌疫苗立场文件(2012年)的基础上,结合国内外研究的最新进展,对肺炎球菌性疾病的病原学、临床学、流行病学、疾病负担、疫苗学等方面进行系统综述,目的是通过肺炎球菌性疾病相关知识的全面系统介绍,提高专业人员防控肺炎球菌性疾病水平,以及在发挥疫苗最佳预防作用与科学使用疫苗方面为公共卫生和预防接种人员提供相关证据。

引用

页码：161 / 191

页数：31

共 151 条

[11] Vaccine Serotypes of Streptococcus pneumoniae with High-level Antibiotic Resistance Isolated More Frequently Seven Years After the Licensure of PCV7 in Beijing [J].

Lyu, Shuang ;

Yao, Kai-hu ;

Dong, Fang ;

Xu, Bao-ping ;

Liu, Gang ;

Wang, Quan ;

Shi, Wei ;

Tong, Jing-jing ;

Shen, Kun-ling ;

Yang, Yong-hong .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2016, 35 (03) :316-321

[12]

Immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccine in Chinese healthy population aged >2?years: A randomized; double-blinded; active control; phase III trial.[J].Yujia Kong;Wei Zhang;Zhiwei Jiang;Ling Wang;Chanjuan Li;Yanping Li;Jielai Xia.Human Vaccines & Immunotherapeutics.2015, 10

[13] Surveillance of adverse events following the introduction of 13-valent pneumococcal conjugate vaccine in infants, and comparison with adverse events following 7-valent pneumococcal conjugate vaccine, in Victoria, Australia [J].

Littlejohn, E. S. ;

Clothier, H. J. ;

Perrett, K. P. ;

Danchin, M. .

HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2015, 11 (07) :1828-1835

[14]

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naïve to pneumococcal vaccination.[J].Jacek Wysocki;Jerzy Brzostek;Henryk Szymański;Bogusław Tetiurka;Ewa Toporowska-Kowalska;Krystyna Wasowska-Królikowska;Denise A. Sarkozy;Peter C. Giardina;William C. Gruber;Emilio A. Emini;Daniel A. Scott.Vaccine.2015, 14

[15]

Choosing between 7-; 10- and 13-valent pneumococcal conjugate vaccines in childhood: A review of economic evaluations (2006–2014).[J].David Bin-Chia Wu;Nathorn Chaiyakunapruk;Huey-Yi Chong;Philippe Beutels.Vaccine.2015, 14

[16]

Two and three doses of the CRM197conjugated 9-valent pneumococcal and meningococcal C combination vaccine in infancy;prime for comparable booster responses at 12months of age..Sigurdartottir S;Davidsdottir K;Arason V;.Proceedings of the 5th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD).2006,

[17] 2015-2016年甘肃省白银市5岁以下儿童社区获得性肺炎疾病负担回顾性调查 [J].